Biotech Unusual Volume: Aldeyra Therapeutics (NASDAQ:ALDX), Alcobra (NASDAQ:ADHD), Receptos (NASDAQ:RCPT), Celsus Therapeutics (NASDAQ:CLTX)

Technology Stocks News 2

Aldeyra Therapeutics Inc (NASDAQ:ALDX) rallied to a new all-time high Thursday after Aegis Capital began coverage of the biotech company working to develop treatments for rare skin and eye diseases with a Buy rating. Aldeyra Therapeutics Inc (NASDAQ:ALDX) stock performance was 12.26% in last session and finished the day at $7.51. Traded volume was 134,905.00million shares in the last session and the average volume of the stock remained 26.32K shares. Aldeyra Therapeutics Inc (NASDAQ:ALDX) insider ownership is 1.20%.

Alcobra Ltd. (NASDAQ:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the JMP Securities Healthcare Conference, taking place June 24-25 in New York City. Alcobra Ltd (NASDAQ:ADHD) dropped -0.47 percent to $18.70 Thursday on volume of 427,396.00million shares. The intra-day range of the stock was $18.32 to $19.50. Alcobra Ltd (NASDAQ:ADHD) has a market capitalization of $255.01million.

Receptos Inc (NASDAQ:RCPT) has announced offering of about 4.43 million common stock shares with the possibility of selling additional 664,950 shares if the demand is high. The underwritten shares are being offered at $40.25 per share to the public, and the offering will close next week on June 24. Receptos Inc (NASDAQ:RCPT)’s stock on June 19, 2014 reported a decrease of -2.76% to the closing price of $39.86. Its fifty two weeks range is $15.21 -$55.00. The total market capitalization recorded $883.67million. The overall volume in the last trading session was 2.17million shares. In its share capital, RCPT has 22.17million outstanding shares.

Celsus Therapeutics Plc (ADR) (NASDAQ:CLTX), an emerging growth, development-stage biotech company, has received approval from the Israeli Ministry of Health to conduct a Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis. On Thursday, shares of Celsus Therapeutics PLC (ADR) (NASDAQ:CLTX) dropped -2.30% to close the day at $6.80. Company monthly performance is recorded as 30.77%. Celsus Therapeutics PLC (ADR) (NASDAQ:CLTX) quarterly revenue growth is -1.45%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone